 |
a live attenuated bioengineered Listeria monocytogenes cancer immunotherapy |
|---|---|
| Trade Name | |
| Orphan Indication | Stage II to IV invasive cervical carcinoma |
| USA Market Approval | USA |
| USA Designation Date | 2014-04-29 00:00:00 |
| Sponsor | Advaxis, Inc.;305 College Road East;Princeton, New Jersey, 08540 |
